Resources from the same session
59MO - Adjuvant Abemaciclib Combined with Endocrine Therapy (ET): Efficacy Results in monarchE Cohort 1
Presenter: Mattea Reinisch
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
60MO - Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): explorative analysis in Penelope-B
Presenter: Jenny Furlanetto
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
91MO - Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials group ANZ 1401 ELIMINATE trial.
Presenter: Nick Murray
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
92MO - Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2_) primary breast cancer (BC): CheckMate 7A8
Presenter: Sara Tolaney
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 59MO, 60MO, 91MO and 92MO
Presenter: Janice Wing-Hang Tsang
Session: Mini Oral session 1
Resources:
Slides
Webcast
93MO - Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
Presenter: Géraldine Gebhart
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 93MO
Presenter: Alessandra Gennari
Session: Mini Oral session 1
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini Oral session 1
Resources:
Webcast